PGK1 and lung adenocarcinoma: In this work, through the systematic analysis of PGK1 in lung adenocarcinoma, we identify that the over-expression of PGK1 may affect the immune microenvironment of LUAD through a tumor metabolic immune interaction, suggesting a potential strategy to improve the efficacy of other immunotherapies; namely, by inhibiting PGK1 or aerobic glycolysis to modify the tumor immune microenvironment.